ORCHPHARMA Orchid Pharma Q1 FY26 results (Apr–Jun 2025) and concall
Orchid Pharma reported a challenging Q1 FY26 with a significant 29% YoY decline in sales to INR 173 crores, primarily due to an unprecedented global slowdown in the antibiotics market. Despite this, the company maintained gross margins at 42% and achieved an operational EBITDA of INR 14 crores. A key strategic development was the acquisition of global rights to Enmetazobactam and the Exblifep trademark from Allecra, positioning Orchid as an innovator of an internationally approved new chemical entity. The company is also progressing with its 7ACA project and expects the Dhanuka Labs merger to
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Revenue | 223 | 217 | 237 | 263 |
| EBITDA | 30 | 26 | 28 | -6 |
| Net profit | 27 | 21 | 22 | -6 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
